The PBS subsidises treatment with idelalisib under the National Health Act 1953, section 85 for patients with CLL.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib.
Applying for initial treatment
To apply for initial authority approval to prescribe PBS-subsidised idelalisib to treat CLL either:
Applying for continuing treatment
To apply for continuing authority approval to prescribe PBS-subsidised idelalisib to treat CLL either:
Call the PBS authority approvals line for further information.